Corporate development in biotechnology in 2005

Journal of Commercial Biotechnology

Volumn 11, Issue 3, 2005, Pages 239-248

  Williams, Alan ^a,b  

^a Managing Resources Ltd   (United Kingdom)

^b OPEN UNIVERSITY BUSINESS SCHOOL   (United Kingdom)

Author keywords

Acquisitions; Business models; Consolidation; Mergers

Indexed keywords

BIOTECHNOLOGY COMPANIES; CORPORATE DEVELOPMENTS;

CONSOLIDATION; PROFESSIONAL ASPECTS;

BIOTECHNOLOGY;

ADALIMUMAB; ANTIOBESITY AGENT; ATL 962; CERTOLIZUMAB PEGOL; ERYTHROPOIETIN; INSULIN; UNCLASSIFIED DRUG; ZANAMIVIR;

ARTICLE; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN GENOME PROJECT; INFLUENZA; LICENSING; MEDICAL RESEARCH; MEDICARE; NONBIOLOGICAL MODEL; PUBLICATION; PURCHASING;

EID: 18044363069     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040123     Document Type: Article

References (17)

1. Williams, A. (1998), 'Is partnering an opportunity for a biotechnology company to grow or does it create risk?', J. Comm. Biotechnol., Vol. 5(1), pp. 12-20.
2. Williams, A. (2001), 'Consolidation', J. Comm. Biotechnol., Vol. 5(2), pp. 106-112.
3. Williams, A. (2001), 'Consolidation revisited', J. Comm. Biotechnol., Vol. 8(2), pp. 130-139.
4. Bialojan, S. and Schüler, J. (2003), 'Commercial biotechnology in Germany: An overview', J. Comm. Biotechnol., Vol. 10(1), pp. 15-21.
5. Stoiber, W. (2003), 'Consolidation challenges in Europe's life science sector - making it happen', J. Comm. Biotechnol., Vol. 10(1), pp. 29-34.
6. Pavlou, A. (2003), 'Biotechnology M&A insight: Deals and strategies', J. Comm. Biotechnol., Vol. 10(1), pp. 85-91.
7. Biotech 2004: Back on Track - Burrill and Company, Figs 2.4 and 2.5.
8. Beer, M. (2004), Personal communication, at ERBI Network Meeting, Cambridge, 23rd September.
9. Madden, J. (2004), The Australian, 6th May.
10. Mitchell, P. Nature Biotechnology, Vol. 32(6), June 2004, pp. 639-640.
11. Burrill, G. S. (ed.) (2004), 'Biotech 2004: Back on Track', Fig 11.7, Burrill & Co. LLC, San Francisco.
12. Leschley, J. (2001), Foreword in 'Integration', Ernst & Young's Eighth Annual European Life Sciences Report, Ernst & Young International.
13. Barnes, K. (2004), interview with Bob Ruffolo, Drug Discovery Today, Vol. 9, No. 15, 1st August, pp. 631-635.
14. Irving, R. (2004), reporting Richard Palmer, The Times, 28th September.
15. Ernst &Young (2004), 'Refocus', June, Ernst & Young, London.
16. URL: www.bio.org/speeches/pubs/er/statistics.asp/, accessed 5th October, 2004.
17. Brooks, W. (2003), 'What will it take to get institutional investors interested in life sciences again?', J. Comm. Biotechnol. , Vol. 10(1), pp. 22-28.